Table 1.
Characteristics of extension study patients at core study baseline
| Secukinumab 300 mg FI (n = 13) | Secukinumab 300 mg RAN (n = 14) | |
|---|---|---|
| Age, years | ||
| Mean ± SD | 52.2 ± 12.70 | 47.9 ± 9.31 |
| Sex, n (%) | ||
| Male | 9 (69.2) | 13 (92.9) |
| Race, n (%) | ||
| Asian | 13 (100) | 14 (100) |
| BMI, kg/m2 | ||
| Mean ± SD | 24.89 ± 2.91 | 25.79 ± 5.58 |
| Bodyweight | ||
| ≤60 kg, n (%) | 5 (38.5) | 0 (0) |
| PASI score | ||
| Absolute mean PASI ± SD | 27.1 ± 10.21 | 23.54 ± 10.44 |
| Previous systemic treatment, n (%) | ||
| Any | 8 (61.5) | 11 (78.6) |
| Biologic | 2 (15.4) | 4 (28.6) |
BMI, body mass index; FI, fixed interval; PASI, Psoriasis Area and Severity Index; RAN, retreatment as needed; SD, standard deviation.